• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Arthur Tzianabos, Ph.D., June Lee, MD FACCP, and Joseph Loscalzo, MD, Ph.D. Join 5AM Ventures

    9/27/22 8:15:00 AM ET
    $AKUS
    $CINC
    $FIXX
    $IONS
    Specialty Chemicals
    Consumer Discretionary
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AKUS alert in real time by email

    SAN FRANCISCO and BOSTON, Sept. 27, 2022 (GLOBE NEWSWIRE) -- 5AM Ventures, a bicoastal venture capital firm, continues to attract preeminent talent as it celebrates 20 years of investing in early-stage life science companies. The firm is currently deploying capital in breakthrough science opportunities throughout North America and Europe from its $450 million 5AM Ventures VII fund and its $300 million 5AM Opportunities II fund, which has an additional mandate to invest in public market opportunities.

    5AM is pleased to announce the addition of two Venture Partners to the firm's investment team, and a Venture Advisor to the advisory team.

    Dr. Arthur Tzianabos has joined 5AM as a Venture Partner, bringing notable scientific and operational experience. Dr. Tzianabos recently served as President and CEO of 5AM portfolio company, Homology Medicines, Inc. (NASDAQ:FIXX) where he led the company from inception through a successful public offering. At Homology he took developmental candidates into gene editing and gene therapy clinical trials and struck many validating business development deals including the creation of a new company based on Homology's innovative AAV process development and manufacturing platform. Previously, Dr. Tzianabos was SVP of Research and Early Development at Shire PLC (acquired by Takeda, for $62B), where he was responsible for building the company's therapeutic pipeline and worked closely with the Venture group to invest in genetic medicines companies. Earlier, Dr. Tzianabos spent 13 years as a principal investigator and faculty member at Harvard Medical School. He is a member of the boards of directors for several companies, including Chair of 5AM's Homology Medicines and Akouos, Inc. (NASDAQ:AKUS). He serves on the Executive Committee of the Board of Directors for the Alliance for Regenerative Medicine and the Development Board for the University of New Hampshire's College of Life Sciences and Agriculture. Dr. Tzianabos received his B.S. in Biology from Boston College and his Ph.D. in Microbiology from the University of New Hampshire.

    Dr. June Lee, an eminent biotechnology industry operator, has joined 5AM as a Venture Partner. Dr. Lee was previously Chief Operating Officer, EVP and Chief Development Officer of MyoKardia (acquired by Bristol Myers Squibb for $13.1B) where she led development for its pipeline, including Camzyos to treat obstructive hyptertrophic cardiomyopathy, which the FDA approved this year. Prior to MyoKardia, Dr. Lee was a Professor of Medicine at UCSF School of Medicine, where she served as Director of Translational Research and built the Catalyst Program, an internal accelerator for early-stage technologies. Previously, Dr. Lee was the therapeutic area head in early clinical development at Genentech including programs in cardiovascular and metabolic diseases, infectious diseases, and respiratory diseases. Currently, she serves on the boards of leading biotech companies, including 5AM's CinCor Pharma, Inc. (NASDAQ:CINC). Dr. Lee received her undergraduate degree in Chemistry at the Johns Hopkins University, her medical degree at the School of Medicine at University of California, Davis, and completed clinical training in internal medicine and pulmonary and critical care at UCLA and UCSF.

    Dr. Joseph Loscalzo, a distinguished academic and industry leader, has joined 5AM as a Venture Advisor. Dr. Loscalzo is a Hersey professor at Harvard Medical School, Chair of the Department of Medicine, and Physician-in-Chief at Brigham and Women's Hospital. He previously served as Chief of Cardiology at Boston University in addition to being Chair of Medicine, Professor of Biochemistry, and Director of the Whitaker Cardiovascular Institute. Dr. Loscalzo has received numerous awards including election to the American Society for Clinical Investigation, the Association of American Physicians, and the Institute of Medicine of the National Academy of Sciences. His breadth of industry leadership experience includes serving as a board director at Leap Therapeutics, Inc. (NASDAQ:LPTX) and as board chair of Ionis Pharmaceuticals (NASDAQ:IONS). Dr. Loscalzo received his Ph.D. in Biochemistry and his M.D. from the University of Pennsylvania.

    ABOUT 5AM VENTURES

    Founded in 2002, 5AM Ventures is a leading venture capital firm focused on building next-generation life science companies. Based in San Francisco and Boston, 5AM takes a hands-on approach to investing and company building, often going beyond traditional board roles to leverage our diverse team of scientists, clinicians, drug developers and executives throughout a company's life. With more than $2.2 billion raised since inception, 5AM has invested globally in over 100 public and private companies. For more information, please visit www.5amventures.com.

    CONTACT

    5AM Ventures

    Britt Inga Emerson, Investor Relations Manager

    Email: [email protected]



    Primary Logo

    Get the next $AKUS alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AKUS
    $CINC
    $FIXX
    $IONS

    CompanyDatePrice TargetRatingAnalyst
    Ionis Pharmaceuticals Inc.
    $IONS
    9/26/2025$65.00Sell → Neutral
    Goldman
    Ionis Pharmaceuticals Inc.
    $IONS
    9/3/2025$70.00Market Perform → Outperform
    BMO Capital Markets
    Ionis Pharmaceuticals Inc.
    $IONS
    7/31/2025$62.00Equal-Weight → Overweight
    Morgan Stanley
    Ionis Pharmaceuticals Inc.
    $IONS
    7/1/2025$57.00Equal Weight → Overweight
    Barclays
    Ionis Pharmaceuticals Inc.
    $IONS
    4/7/2025$45.00Buy
    H.C. Wainwright
    Ionis Pharmaceuticals Inc.
    $IONS
    3/31/2025$39.00Neutral
    Redburn Atlantic
    Leap Therapeutics Inc.
    $LPTX
    1/29/2025Buy → Neutral
    H.C. Wainwright
    Leap Therapeutics Inc.
    $LPTX
    1/29/2025$9.00 → $1.25Outperform → Neutral
    Robert W. Baird
    More analyst ratings

    $AKUS
    $CINC
    $FIXX
    $IONS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Leap Therapeutics to Present Final Clinical Data from Part B of the DeFianCe Study at the ESMO Congress 2025

    CAMBRIDGE, Mass., Sept. 25, 2025 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced it will present the final clinical results from Part B of the DeFianCe study (NCT05480306), a Phase 2 study of sirexatamab (DKN-01), an anti-DKK1 monoclonal antibody, in combination with bevacizumab and chemotherapy (Sirexatamab Arm) compared to bevacizumab and chemotherapy (Control Arm) in patients with advanced microsatellite stable (MSS) colorectal cancer (CRC) who have received one prior systemic therapy for advanced disease. The final results will be presented in a Mini Oral Session at the Europe

    9/25/25 7:00:00 AM ET
    $LPTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Biogen Provides Regulatory Update on High Dose Regimen of Nusinersen

    CAMBRIDGE, Mass., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ:BIIB) today announced that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) for the Company's supplemental New Drug Application (sNDA) for the high dose regimen of nusinersen for the treatment of spinal muscular atrophy (SMA). The FDA letter requested an update to the technical information be included in the Chemistry Manufacturing and Controls (CMC) module of the sNDA. The letter did not cite any deficiencies in the clinical data of the high dose regimen. The FDA provided options for resolution, and Biogen is planning to resubmit the application promptly based upon readily availabl

    9/23/25 4:30:00 PM ET
    $BIIB
    $IONS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Ionis announces positive topline results from pivotal study of zilganersen in Alexander disease

    – First and only investigational medicine to demonstrate a clinically meaningful and disease-modifying impact on this rare, often fatal neurological condition – – NDA submission planned in Q1 2026 – Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) today announced positive topline results from the pivotal study of zilganersen in children and adults living with Alexander disease (AxD), a rare, progressive and often fatal neurological condition with no approved disease-modifying treatments. Zilganersen 50 mg demonstrated statistically significant and clinically meaningful stabilization on the primary endpoint of gait speed as assessed by the 10-Meter Walk Test (10MWT) compared to control at week

    9/22/25 7:00:00 AM ET
    $IONS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKUS
    $CINC
    $FIXX
    $IONS
    SEC Filings

    View All

    SEC Form 144 filed by Ionis Pharmaceuticals Inc.

    144 - IONIS PHARMACEUTICALS INC (0000874015) (Subject)

    9/30/25 4:49:22 PM ET
    $IONS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ionis Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - IONIS PHARMACEUTICALS INC (0000874015) (Filer)

    9/22/25 7:05:51 AM ET
    $IONS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Leap Therapeutics Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

    8-K - LEAP THERAPEUTICS, INC. (0001509745) (Filer)

    9/11/25 4:31:09 PM ET
    $LPTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKUS
    $CINC
    $FIXX
    $IONS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Ionis Pharma upgraded by Goldman with a new price target

    Goldman upgraded Ionis Pharma from Sell to Neutral and set a new price target of $65.00

    9/26/25 8:00:14 AM ET
    $IONS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ionis Pharma upgraded by BMO Capital Markets with a new price target

    BMO Capital Markets upgraded Ionis Pharma from Market Perform to Outperform and set a new price target of $70.00

    9/3/25 8:16:13 AM ET
    $IONS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ionis Pharma upgraded by Morgan Stanley with a new price target

    Morgan Stanley upgraded Ionis Pharma from Equal-Weight to Overweight and set a new price target of $62.00

    7/31/25 7:07:33 AM ET
    $IONS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKUS
    $CINC
    $FIXX
    $IONS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP CLO & General Counsel O'Neil Patrick R. exercised 1,700 shares at a strike of $56.78 and sold $109,787 worth of shares (1,700 units at $64.58) (SEC Form 4)

    4 - IONIS PHARMACEUTICALS INC (0000874015) (Issuer)

    9/16/25 4:56:38 PM ET
    $IONS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP, Chief Business Officer Baroldi Joseph exercised 11,950 shares at a strike of $31.80 and sold $742,838 worth of shares (11,950 units at $62.16) (SEC Form 4)

    4 - IONIS PHARMACEUTICALS INC (0000874015) (Issuer)

    9/11/25 5:05:07 PM ET
    $IONS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP CLO & General Counsel O'Neil Patrick R. exercised 21,000 shares at a strike of $60.69 and sold $1,355,661 worth of shares (21,000 units at $64.56) (SEC Form 4)

    4 - IONIS PHARMACEUTICALS INC (0000874015) (Issuer)

    9/11/25 5:04:46 PM ET
    $IONS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKUS
    $CINC
    $FIXX
    $IONS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Hayden Michael R bought $477,900 worth of shares (15,000 units at $31.86), increasing direct ownership by 43% to 50,219 units (SEC Form 4)

    4 - IONIS PHARMACEUTICALS INC (0000874015) (Issuer)

    5/2/25 4:38:26 PM ET
    $IONS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Hayden Michael R bought $181,079 worth of shares (5,000 units at $36.22), increasing direct ownership by 17% to 35,219 units (SEC Form 4)

    4 - IONIS PHARMACEUTICALS INC (0000874015) (Issuer)

    12/26/24 4:57:52 PM ET
    $IONS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKUS
    $CINC
    $FIXX
    $IONS
    Financials

    Live finance-specific insights

    View All

    Leap Therapeutics Reports Second Quarter 2025 Financial Results

    CAMBRIDGE, Mass., Aug. 14, 2025 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the second quarter of 2025. Leap Highlights: Board of Directors initiated process of exploring strategic alternatives to maximize shareholder valueStrategic restructuring to prioritize corporate development resulting in a further 75% reduction in workforceReported updated data from the randomized, controlled Part B of the Phase 2 DeFianCe study of sirexatamab (DKN-01) plus bevacizumab and chemotherapy in second-line colorectal cancer (CRC)"This past quarter, we undertook a strategic

    8/14/25 7:00:00 AM ET
    $LPTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ionis reports second quarter 2025 financial results and highlights progress on key programs

    - TRYNGOLZATM delivers $19 million in net product sales in the second quarter 2025 - - Donidalorsen approval in hereditary angioedema (HAE) anticipated next month; Ionis' second independent launch - - Phase 3 data from the pivotal CORE and CORE2 studies in severe hypertriglyceridemia (sHTG) expected in September 2025 - - Increasing 2025 financial guidance based on strong performance and improved outlook - Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) (the "Company") today reported financial results and provided key updates for the second quarter ended June 30, 2025. "During the second quarter, we continued to build momentum across our business," said Brett P. Monia, Ph.D., chief execu

    7/30/25 7:00:00 AM ET
    $IONS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results

    Salanersen (BIIB115/ION306) is a novel antisense oligonucleotide (ASO) with the potential to achieve high efficacy and once yearly dosing in spinal muscular atrophy (SMA)Interim Phase 1 data show children with SMA previously treated with gene therapy experienced a substantial slowing of neurodegeneration and clinically meaningful improvements in motor function following initiation of salanersenBased on these encouraging Phase 1 data, Biogen is engaging with regulators to advance salanersen to registrational stage studies, building on extensive experience in SMA CAMBRIDGE, Mass., June 25, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ:BIIB) announced topline results from the Phase 1 study of

    6/25/25 7:30:37 AM ET
    $BIIB
    $IONS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $AKUS
    $CINC
    $FIXX
    $IONS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Ionis Pharmaceuticals Inc.

    SC 13G/A - IONIS PHARMACEUTICALS INC (0000874015) (Subject)

    11/14/24 8:34:57 PM ET
    $IONS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Ionis Pharmaceuticals Inc.

    SC 13G/A - IONIS PHARMACEUTICALS INC (0000874015) (Subject)

    11/14/24 1:28:29 PM ET
    $IONS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Leap Therapeutics Inc.

    SC 13G - LEAP THERAPEUTICS, INC. (0001509745) (Subject)

    11/14/24 6:07:56 AM ET
    $LPTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKUS
    $CINC
    $FIXX
    $IONS
    Leadership Updates

    Live Leadership Updates

    View All

    Alltrna Announces Updates to Its Board of Directors

    Chris Schade appointed as Board ChairpersonLynne Parshall, Robert Plenge, M.D., Ph.D., and Nancy Simonian, M.D., appointed to Board of DirectorsCAMBRIDGE, Mass., July 17, 2024 /PRNewswire/ -- Alltrna, a Flagship Pioneering company unlocking transfer RNA (tRNA) biology and pioneering tRNA therapeutics to regulate the protein universe and resolve disease, today announced the appointment of Chris Schade, Growth Partner at Flagship Pioneering, as Chairperson of the Board, succeeding Noubar Afeyan, Ph.D., Co-Founder of Alltrna and Founder and CEO of Flagship Pioneering. In addition, Alltrna also announced the appointments to the company's Board of Directors of Lynne Parshall, founding Chief Opera

    7/17/24 8:00:00 AM ET
    $APRE
    $CYTK
    $EVLO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments
    Biotechnology: Biological Products (No Diagnostic Substances)

    Contineum Therapeutics Announces Appointment of Sarah Boyce to Board of Directors

    Contineum Therapeutics, Inc. (NASDAQ:CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced the appointment of Sarah Boyce, President and Chief Executive Officer of Avidity Biosciences, Inc. (NASDAQ:RNA), as an independent member of its Board of Directors. Ms. Boyce brings over 25 years of global commercial and clinical development expertise in the life sciences industry to Contineum's board. Ms. Boyce has extensive expertise in global pharmaceut

    6/24/24 4:05:00 PM ET
    $CTNM
    $IONS
    $NVS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Major Pharmaceuticals
    Medicinal Chemicals and Botanical Products

    Ionis announces the appointment of Michael Yang to Board of Directors

    CARLSBAD, Calif., Dec. 14, 2023 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) today announced the appointment of Michael Yang, an experienced biopharmaceutical executive, to the Ionis Board of Directors. Mr. Yang's appointment expands the total number of Ionis Board members to 10. Mr. Yang has more than 20 years of broad senior level leadership experience in biotech, pharmaceutical and medical device companies, where he launched new platforms, expanded global revenues and diversified product lines. He most recently served as President, Chief Executive Officer and B

    12/14/23 4:05:00 PM ET
    $IONS
    Biotechnology: Pharmaceutical Preparations
    Health Care